1-12 of 12
Alessandra Decio
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B068: FOXM1 mediates the crosstalk between tumor microenvironment and ovarian cancer stem cells as revealed by patient-derived organotypic models

Chiara Battistini, Hilary A. Kenny, Valentina Nieddu, Valentina Melocchi, Alessandra Decio, Beatrice Malacrida, Alessia Gatto, Fabrizio Bianchi, Raffaella Giavazzi, Nicoletta Colombo, Frances R. Balkwill, Ernst Lengyel, Ugo Cavallaro
Journal: Cancer Research
Cancer Res (2024) 84 (5_Supplement_2): B068.
https://doi.org/10.1158/1538-7445.OVARIAN23-B068
Published: 04 March 2024
View article titled, Abstract B068: FOXM1 mediates the crosstalk between tumor microenvironment and ovarian cancer stem cells as revealed by patient-derived organotypic models
Journal Articles

Abstract 4838: Exploiting mitochondrial metabolism to enhance the response to standard of care treatments in ovarian cancer

Laura Formenti, Alessandra Decio, Valentina Dematteis, Giulia Dellavedova, Maria Rosa Bani, Raffaella Giavazzi, Carmen Ghilardi
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 4838.
https://doi.org/10.1158/1538-7445.AM2023-4838
Published: 04 April 2023
View article titled, Abstract 4838: Exploiting mitochondrial metabolism to enhance the response to standard of care treatments in ovarian cancer
Journal Articles

Abstract 6113: Predictive value of HRD testing on the response to PARP inhibitors in ovarian cancer preclinical models

Giulia Dellavedova, Alessandra Decio, Laura Formenti, Luca Porcu, Carmen Ghilardi, Raffaella Giavazzi, Maria Rosa Bani
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6113.
https://doi.org/10.1158/1538-7445.AM2023-6113
Published: 04 April 2023
View article titled, Abstract 6113: Predictive value of HRD testing on the response to PARP inhibitors in ovarian cancer preclinical models
Journal Articles

Abstract 3237: Combining PARP inhibition with the polo-like kinase 1 (PLK1) inhibitor onvansertib overcomes PARP inhibitor resistance

Michela Chiappa, Federica Guffanti, Alessandra Decio, Alessandro Aliverti, Francesca Ricci, Eugenio Scanziani, Federica Camin, Ilaria Craparotta, Maria Chiara Barbera, Marco Bolis, Maya Ridinger, Giovanna Damia
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 3237.
https://doi.org/10.1158/1538-7445.AM2022-3237
Published: 15 June 2022
View article titled, Abstract 3237: Combining PARP inhibition with the polo-like kinase 1 (PLK1) inhibitor onvansertib overcomes PARP inhibitor resistance
Journal Articles

PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer

Carmen Ghilardi, Catarina Moreira-Barbosa, Laura Brunelli, Paola Ostano, Nicolò Panini, Monica Lupi, Alessia Anastasia, Fabio Fiordaliso, Monica Salio, Laura Formenti, Massimo Russo, Edoardo Arrigoni, Ferdinando Chiaradonna, Giovanna Chiorino, Giulio Draetta, Joseph R. Marszalek, Christopher P. Vellano, Roberta Pastorelli, MariaRosa Bani, Alessandra Decio, Raffaella Giavazzi
Journal: Cancer Research
Cancer Res (2022) 82 (7): 1423–1434.
https://doi.org/10.1158/0008-5472.CAN-21-1223
Published: 01 April 2022
View article titled, PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer
Open the PDF for PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 2406: Metabolic phenotype and metastasis in patient-derived ovarian cancer xenografts

MariaRosa Bani, Carmen Ghilardi, Alessandra Decio, Alessia Anastasia, Martina Verza, Stefano Indraccolo, Raffaella Giavazzi
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2406.
https://doi.org/10.1158/1538-7445.AM2018-2406
Published: 01 July 2018
View article titled, Abstract 2406: Metabolic phenotype and metastasis in patient-derived ovarian cancer xenografts
Journal Articles

Abstract 2816: Patient derived ovarian cancer xenograft (OC-PDX) to study the response of the PARP inhibitor olaparib

Francesca Bizzaro, Alessia C. Marchetti, Alessandra Decio, Francesca Ricci, Mark J. O'Connor, Molly A. Taylor, Zhongwu Lai, Simon T. Barry, Maria R. Bani, Raffaella Giavazzi
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2816.
https://doi.org/10.1158/1538-7445.AM2018-2816
Published: 01 July 2018
View article titled, Abstract 2816: Patient derived ovarian cancer xenograft (OC-PDX) to study the response of the PARP inhibitor olaparib
Journal Articles

Abstract 3377: Bevacizumab-improved distribution of paclitaxel in ovarian cancer xenografts potentiates antitumor efficacy

Marta Cesca, Lavinia Morosi, Alexander Berndt, Ilaria Fuso Nerini, Alessandra Decio, Massimo Zucchetti, Raffaella Giavazzi
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3377.
https://doi.org/10.1158/1538-7445.AM2016-3377
Published: 15 July 2016
View article titled, Abstract 3377: Bevacizumab-improved distribution of paclitaxel in ovarian cancer xenografts potentiates antitumor efficacy
Journal Articles

Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations

Francesca Ricci, Francesca Bizzaro, Marta Cesca, Federica Guffanti, Monica Ganzinelli, Alessandra Decio, Carmen Ghilardi, Patrizia Perego, Robert Fruscio, Alessandro Buda, Rodolfo Milani, Paola Ostano, Giovanna Chiorino, Maria Rosa Bani, Giovanna Damia, Raffaella Giavazzi
Journal: Cancer Research
Cancer Res (2014) 74 (23): 6980–6990.
https://doi.org/10.1158/0008-5472.CAN-14-0274
Published: 30 November 2014
View article titled, Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations
Open the PDF for Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations in another window
Includes: Supplementary data
Journal Articles

Abstract 2994: Cediranib affects tumor progression and survival of mice bearing patient derived ovarian carcinoma xenografts (EOC-PDX)

Alessandra Decio, Marta Cesca, Francesca Bizzaro, Dorina Belotti, Raffaella Giavazzi
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2994.
https://doi.org/10.1158/1538-7445.AM2014-2994
Published: 01 October 2014
View article titled, Abstract 2994: Cediranib affects tumor progression and survival of mice bearing patient derived ovarian carcinoma xenografts (EOC-PDX)
Journal Articles

Abstract 5096: Heterogeneous response to antiangiogenic therapy in ovarian cancer xenografts: a tool to investigate biomarkers of resistance.

Alessandra Decio, Marta Cesca, Francesca Bizzaro, Valentina Scarlato, Carmen Ghilardi, Maria Rosa Bani, Raffaella Giavazzi
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 5096.
https://doi.org/10.1158/1538-7445.AM2013-5096
Published: 15 April 2013
View article titled, Abstract 5096: Heterogeneous response to antiangiogenic therapy in ovarian cancer xenografts: a tool to investigate biomarkers of resistance.
Journal Articles

Abstract 3516: Combinations of chemotherapy with bevacizumab in a xenograft model of human ovarian carcinoma

Paolo Oliva, Alessandra Decio, Vittoria Castiglioni, Andrea Bassi, Dorina Belotti, Maria Rosa Bani, Raffaella Giavazzi
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 3516.
https://doi.org/10.1158/1538-7445.AM2011-3516
Published: 15 April 2011
View article titled, Abstract 3516: Combinations of chemotherapy with bevacizumab in a xenograft model of human ovarian carcinoma